(MedPage Today) — The FDA approved a label update with a new titration schedule for donanemab (Kisunla), an anti-amyloid drug approved to treat early symptomatic Alzheimer’s disease, drugmaker Eli Lilly said.
The move was designed to reduce the…
Source link : https://www.medpagetoday.com/neurology/alzheimersdisease/116438
Author :
Publish date : 2025-07-09 21:08:00
Copyright for syndicated content belongs to the linked Source.
